Developer docs
API playgroundTry for free, no card

Search company profiles

TG Therapeutics

Full company profile

uuid00025o4

Namestring
TG Therapeutics
Legal namestring
TG Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, focused on developing therapeutics for B-cell mediated diseases, with current commercial emphasis on relapsing forms of multiple sclerosis. The company's lead and only marketed product is BRIUMVI (ublituximab-xiiy), an FDA-approved (January 2023) glycoengineered anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity (ADCC) via removal of fucose sugar residues. BRIUMVI is administered as an intravenous infusion every six months after initial dosing and generated $594.1 million in US net product revenue in 2025 (92% YoY growth), with over 25,000 patients treated globally.

The company's pipeline leverages two distinct technology platforms: the glycoengineered anti-CD20 antibody platform (currently marketed as IV BRIUMVI, plus a subcutaneous formulation in Phase 3 with self-administration potential) and an allogeneic CAR-T platform centered on azercabtagene zapreleucel (azer-cel), a CD19-directed off-the-shelf cell therapy in Phase 1 for progressive MS and other autoimmune conditions, licensed from Precision BioSciences. Clinical differentiation is supported by a 56.7% reduction in annualized relapse rate versus teriflunomide, a 0.020 annualized relapse rate at Year 5, and 92% of patients progression-free at Year 5.

TG Therapeutics monetizes BRIUMVI through a direct US sales force targeting neurologists and MS treatment centers, with prescription pricing negotiated bilaterally through insurance carriers, PBMs, and healthcare systems rather than publicly listed. International commercialization is executed via a partnership with Neuraxpharm covering the EU, UK, Switzerland, Australia, Kuwait, and UAE. Secondary revenue derives from licensing and milestone payments tied to the azer-cel program. The company has reached profitability with $19.8M in Q1 2026 net income and EPS of $2.87, supported by a $750M senior secured credit facility (expandable to $1B) from Blue Owl Capital secured in March 2026 that provides non-dilutive growth capital alongside an expanded $300M share repurchase authorization.

Short descriptiontext

TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multiple sclerosis therapeutics, monoclonal antibody therapy, biopharmaceutical products, CAR-T cell therapy, autoimmune disease drugs
Industry1 code
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Multiple Sclerosis Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1BRIUMVI Product Sales
TypeSubscription Recurring
Description

Commercial revenue from sales of FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis. Revenue has grown from $89 million in 2023 to $594 million in 2025 (U.S. net product revenue), with 2026 guidance of $885-900 million.

investors.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing agreements including milestone payments from Precision BioSciences for azer-cel development progress ($7.5 million milestone received in March 2026), with up to $288 million in additional milestones available under the agreement.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BRIUMVI
Description

FDA-approved brand name for ublituximab-xiiy, used for treatment of relapsing forms of multiple sclerosis

tgtherapeutics.com
Core offering1 text field

TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 56.7% reduction in annualized relapse rate compared to teriflunomide in treatment-naive patients
+4 more records
Product overview1 text field

TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases, primarily multiple sclerosis. The company markets BRIUMVI (ublituximab-xiiy), an FDA-approved glycoengineered anti-CD20 monoclonal antibody delivered via IV infusion for relapsing forms of MS. The pipeline includes a subcutaneous formulation of ublituximab in Phase 3 development for at-home self-administration, and azercabtagene zapreleucel (azer-cel), a CD19-directed allogeneic CAR-T cell therapy in Phase 1 for progressive MS and other autoimmune conditions.

Product and service3 records
1BRIUMVI (ublituximab-xiiy)
CategoryMultiple Sclerosis Therapeutics
Description

FDA-approved glycoengineered anti-CD20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Administered via intravenous infusion (typically every six months after initial dosing). Sold to neurologists and MS treatment centers across the United States and through Neuraxpharm internationally.

2Subcutaneous Ublituximab
CategoryMultiple Sclerosis Therapeutics (Pipeline)
Description

Subcutaneous formulation of ublituximab being evaluated in Phase 3 clinical trials for adults with relapsing multiple sclerosis. Designed for self-administration via subcutaneous injection (every 8 or 12 weeks), offering an at-home treatment option as an alternative to IV infusion.

3Azercabtagene zapreleucel (azer-cel)
CategoryCell Therapy / Autoimmune Disease (Pipeline)
Description

CD19-directed allogeneic CAR-T cell therapy being developed for B-cell mediated autoimmune conditions including progressive multiple sclerosis. Uses healthy donor T cells modified with proprietary gene-editing technology to express CD19-directed CAR while minimizing graft-versus-host disease (GvHD) risk, enabling off-the-shelf availability.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

TG Therapeutics holds exclusive worldwide rights to develop and commercialize azer-cel (azercabtagene zapreleucel) in autoimmune diseases through licensing agreement with Precision BioSciences. TG paid $7.5 million milestone for Phase 1 trial progress in progressive MS, with up to $288 million in additional milestones plus royalties available.

2Neuraxpharm
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Collaboration with Neuraxpharm for European and international commercialization of BRIUMVI. The partnership expanded commercialization across European Union, United Kingdom, Switzerland, Australia, Kuwait, and United Arab Emirates following initial European regulatory approvals.

finance.yahoo.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets teriflunomide (Aubagio), the active comparator used in BRIUMVI's pivotal ULTIMATE I & II trials. Competes in the same MS treatment paradigm as TG Therapeutics.

TypeEmerging player
Description

Allogeneic CAR-T developer with pipeline programs targeting autoimmune diseases. Competes in the same allogeneic CAR-T autoimmune space as TG's azer-cel.

TypeDirect peer
Description

Maker of Ocrevus (ocrelizumab), the leading anti-CD20 monoclonal antibody for relapsing MS and the primary head-to-head competitor to BRIUMVI. Direct product overlap, same patient population, similar mechanism of action.

TypeDirect peer
Description

Markets Kesimpta (ofatumumab), a subcutaneous anti-CD20 monoclonal antibody for relapsing MS. Competes head-to-head with BRIUMVI on anti-CD20 mechanism with the convenience advantage of self-administered subcutaneous injection.

TypeBroad incumbent
Description

Long-established MS franchise with TYSABRI, AVONEX, PLEGRIDY, and VUMERITY serving the same relapsing MS patient population as BRIUMVI. Major incumbent in MS treatment with broad portfolio and deep neurologist relationships.

TypeDirect peer
Description

Markets Mavenclad (cladribine) for relapsing MS, an oral disease-modifying therapy competing for the same high-efficacy patient segment as BRIUMVI. Direct commercial overlap in the relapsing MS market.

7Bristol Myers Squibb
TypeDirect peer
Description

Markets Zeposia (ozanimod) for relapsing MS, an oral S1P receptor modulator. Direct competitor targeting the same relapsing MS patient population with a differentiated oral mechanism.

TypeEmerging player
Description

Developing allogeneic CAR-T cell therapies for autoimmune diseases, directly overlapping with TG's azer-cel program in progressive MS and broader B-cell mediated autoimmune indications.

TypeEmerging player
Description

Clinical-stage biotech developing CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus and other B-cell mediated conditions. Overlapping target indications with TG's azer-cel program.

TypeOthers
Description

Licensor of azer-cel technology to TG Therapeutics. Partner with material economic interest in azer-cel milestones (up to $288M plus royalties) and recent equity investment from TG.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TG Therapeutics

Multiple Sclerosis Therapeuticstgtherapeutics.com

TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.

What TG Therapeutics does

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, focused on developing therapeutics for B-cell mediated diseases, with current commercial emphasis on relapsing forms of multiple sclerosis. The company's lead and only marketed product is BRIUMVI (ublituximab-xiiy), an FDA-approved (January 2023) glycoengineered anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity (ADCC) via removal of fucose sugar residues. BRIUMVI is administered as an intravenous infusion every six months after initial dosing and generated $594.1 million in US net product revenue in 2025 (92% YoY growth), with over 25,000 patients treated globally.

The company's pipeline leverages two distinct technology platforms: the glycoengineered anti-CD20 antibody platform (currently marketed as IV BRIUMVI, plus a subcutaneous formulation in Phase 3 with self-administration potential) and an allogeneic CAR-T platform centered on azercabtagene zapreleucel (azer-cel), a CD19-directed off-the-shelf cell therapy in Phase 1 for progressive MS and other autoimmune conditions, licensed from Precision BioSciences. Clinical differentiation is supported by a 56.7% reduction in annualized relapse rate versus teriflunomide, a 0.020 annualized relapse rate at Year 5, and 92% of patients progression-free at Year 5.

TG Therapeutics monetizes BRIUMVI through a direct US sales force targeting neurologists and MS treatment centers, with prescription pricing negotiated bilaterally through insurance carriers, PBMs, and healthcare systems rather than publicly listed. International commercialization is executed via a partnership with Neuraxpharm covering the EU, UK, Switzerland, Australia, Kuwait, and UAE. Secondary revenue derives from licensing and milestone payments tied to the azer-cel program. The company has reached profitability with $19.8M in Q1 2026 net income and EPS of $2.87, supported by a $750M senior secured credit facility (expandable to $1B) from Blue Owl Capital secured in March 2026 that provides non-dilutive growth capital alongside an expanded $300M share repurchase authorization.

TG Therapeutics firmographics

Firmographics
Name
TG Therapeutics
Legal name
TG Therapeutics, Inc.
Website
https://tgtherapeutics.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
501–1,000 employees
Short description
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.
Ownership category
akta.pro rank

TG Therapeutics industry classification

Industry
Product category
Multiple Sclerosis Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Multiple sclerosis therapeutics
  • Monoclonal antibody therapy
  • Biopharmaceutical products
  • CAR-T cell therapy
  • Autoimmune disease drugs

Where TG Therapeutics is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TG Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. BRIUMVI Product Sales: Commercial revenue from sales of FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis. Revenue has grown from $89 million in 2023 to $594 million in 2025 (U.S. net product revenue), with 2026 guidance of $885-900 million.
  2. Licensing and Milestone Payments: Revenue from licensing agreements including milestone payments from Precision BioSciences for azer-cel development progress ($7.5 million milestone received in March 2026), with up to $288 million in additional milestones available under the agreement.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

TG Therapeutics product offering

Product offering

Core offering

TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.

Product overview

TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases, primarily multiple sclerosis. The company markets BRIUMVI (ublituximab-xiiy), an FDA-approved glycoengineered anti-CD20 monoclonal antibody delivered via IV infusion for relapsing forms of MS. The pipeline includes a subcutaneous formulation of ublituximab in Phase 3 development for at-home self-administration, and azercabtagene zapreleucel (azer-cel), a CD19-directed allogeneic CAR-T cell therapy in Phase 1 for progressive MS and other autoimmune conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • BRIUMVI: FDA-approved brand name for ublituximab-xiiy, used for treatment of relapsing forms of multiple sclerosis

Products and services

  • BRIUMVI (ublituximab-xiiy) FDA-approved glycoengineered anti-CD20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Administered via intravenous infusion (typically every six months after initial dosing). Sold to neurologists and MS treatment centers across the United States and through Neuraxpharm internationally.
  • Subcutaneous Ublituximab Subcutaneous formulation of ublituximab being evaluated in Phase 3 clinical trials for adults with relapsing multiple sclerosis. Designed for self-administration via subcutaneous injection (every 8 or 12 weeks), offering an at-home treatment option as an alternative to IV infusion.
  • Azercabtagene zapreleucel (azer-cel) CD19-directed allogeneic CAR-T cell therapy being developed for B-cell mediated autoimmune conditions including progressive multiple sclerosis. Uses healthy donor T cells modified with proprietary gene-editing technology to express CD19-directed CAR while minimizing graft-versus-host disease (GvHD) risk, enabling off-the-shelf availability.

Quantifiable outcome

  • 56.7% reduction in annualized relapse rate compared to teriflunomide in treatment-naive patients
  • +4 more outcomes

Companies that use TG Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

TG Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

TG Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Precision BioSciencescoreStrategic or Co-development Partner · 1 January 2024TG Therapeutics holds exclusive worldwide rights to develop and commercialize azer-cel (azercabtagene zapreleucel) in autoimmune diseases through licensing agreement with Precision BioSciences. TG paid $7.5 million milestone for Phase 1 trial progress in progressive MS, with up to $288 million in additional milestones plus royalties available.
  • NeuraxpharmcoreChannel Partner/ Reseller/ Distributor · 1 January 2023Collaboration with Neuraxpharm for European and international commercialization of BRIUMVI. The partnership expanded commercialization across European Union, United Kingdom, Switzerland, Australia, Kuwait, and United Arab Emirates following initial European regulatory approvals.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

TG Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sanofi: Markets teriflunomide (Aubagio), the active comparator used in BRIUMVI's pivotal ULTIMATE I & II trials. Competes in the same MS treatment paradigm as TG Therapeutics.
  • Genentech (Roche): Maker of Ocrevus (ocrelizumab), the leading anti-CD20 monoclonal antibody for relapsing MS and the primary head-to-head competitor to BRIUMVI. Direct product overlap, same patient population, similar mechanism of action.
  • Novartis: Markets Kesimpta (ofatumumab), a subcutaneous anti-CD20 monoclonal antibody for relapsing MS. Competes head-to-head with BRIUMVI on anti-CD20 mechanism with the convenience advantage of self-administered subcutaneous injection.
  • EMD Serono (Merck KGaA): Markets Mavenclad (cladribine) for relapsing MS, an oral disease-modifying therapy competing for the same high-efficacy patient segment as BRIUMVI. Direct commercial overlap in the relapsing MS market.
  • Bristol Myers Squibb: Markets Zeposia (ozanimod) for relapsing MS, an oral S1P receptor modulator. Direct competitor targeting the same relapsing MS patient population with a differentiated oral mechanism.

Emerging players

  • Allogene Therapeutics: Allogeneic CAR-T developer with pipeline programs targeting autoimmune diseases. Competes in the same allogeneic CAR-T autoimmune space as TG's azer-cel.
  • CRISPR Therapeutics: Developing allogeneic CAR-T cell therapies for autoimmune diseases, directly overlapping with TG's azer-cel program in progressive MS and broader B-cell mediated autoimmune indications.
  • Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus and other B-cell mediated conditions. Overlapping target indications with TG's azer-cel program.

Broad incumbents

  • Biogen: Long-established MS franchise with TYSABRI, AVONEX, PLEGRIDY, and VUMERITY serving the same relapsing MS patient population as BRIUMVI. Major incumbent in MS treatment with broad portfolio and deep neurologist relationships.

Others

  • Precision BioSciences: Licensor of azer-cel technology to TG Therapeutics. Partner with material economic interest in azer-cel milestones (up to $288M plus royalties) and recent equity investment from TG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

TG Therapeutics social profiles

Digital presence

TG Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TG Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

TG Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TG Therapeutics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TG Therapeutics

What does TG Therapeutics do?

TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.

Is TG Therapeutics a public or private company?

TG Therapeutics is a public company. It is classified as public and is currently operating.

When was TG Therapeutics founded?

TG Therapeutics was founded in 2012. It employs 501 to 1,000 people.

Where is TG Therapeutics based?

TG Therapeutics is headquartered in Morrisville, United States, in the North America region.

How does TG Therapeutics make money?

Two revenue lines are on record. BRIUMVI Product Sales are the primary driver. The others are licensing and Milestone Payments.

Who are TG Therapeutics's main competitors?

Direct peers on record are Sanofi, Genentech (Roche), Novartis, EMD Serono (Merck KGaA) and Bristol Myers Squibb. Emerging players are Allogene Therapeutics, CRISPR Therapeutics and Cabaletta Bio. Biogen is listed as a broad incumbent. Precision BioSciences is listed as an others.

Does TG Therapeutics have an API?

No public API is recorded for TG Therapeutics.

What industry is TG Therapeutics in?

TG Therapeutics's product category is Multiple Sclerosis Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BNNJulien Nono-Womdim’s Top Picks for Nov. 18, 2026Julien Nono-Womdim, equity analyst at Goodreid, shares his Nov. 18, 2026 U.S. equity outlook, citing a repriced market and earnings growth. He recommends TG Therapeutics, Medpace Holdings, and United Natural Foods, citing AI-driven demand and recession-resistant food distribution. He expects S&P 500 profits to grow about a third this year.Business Wire BlogTG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™TG Therapeutics ranked fifth on the 2026 Deloitte Technology Fast 500, its third consecutive year. The ranking reflects growth driven by BRIUMVI revenues, approved for relapsing multiple sclerosis in December 2022. The company continues its mission to develop treatment alternatives for B-cell diseases.FinancialContent Business PageTG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™TG Therapeutics ranked number 5 on the Deloitte Technology Fast 500 for the third consecutive year, citing BRIUMVI revenues from its FDA-approved treatment for relapsing multiple sclerosis. The ranking is based on fiscal 2022-2025 revenue growth, with BRIUMVI approved in December 2022.Defense World110,365 TG Therapeutics, Inc. $TGTX Shares Acquired by Fifth Third BancorpFifth Third Bancorp raised its TG Therapeutics stake by 181.1% in Q3, buying 110,365 shares. TG Therapeutics reported Q3 EPS of $0.35, missing the $0.36 consensus, with revenue of $259.94 million, up 60.8% year-over-year. Analysts have an average "Moderate Buy" rating with a $63 target.NasdaqTG Therapeutics: 3 Key Takeaways for Long-Term InvestorsTG Therapeutics raised its full-year 2026 global revenue guidance to $1 billion, citing 52% year-over-year U.S. BRIUMVI net product revenue growth. The company also highlighted a subcutaneous formulation that could more than double peak sales opportunity and a single-dose IV initiation plan. Management expects Q4 momentum to push the annualized run rate above $1 billion.YahooTG Therapeutics: 3 Key Takeaways for Long-Term InvestorsTG Therapeutics raised its full-year 2026 global revenue guidance to $1 billion on its Q3 2026 earnings call. U.S. BRIUMVI revenue grew 52% year over year, with Q3 U.S. net product revenue at $233 million. Management plans a subcutaneous formulation and single-dose IV initiation to drive further demand.The Motley FoolTG Therapeutics: 3 Key Takeaways for Long-Term InvestorsTG Therapeutics raised its full-year 2026 global revenue guidance to $1 billion on its Q3 2026 earnings call. U.S. BRIUMVI revenue rose 52% year over year, reaching $233 million in Q3. Management plans a subcutaneous formulation and single-dose IV initiation to drive further demand.Defense WorldTG Therapeutics, Inc. $TGTX Shares Newly Acquired by Ashton Thomas Private Wealth LLCAshton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics during Q3, purchasing 8,906 shares valued at approximately $497,000. Analysts have set an average price target of $63.00, with an average rating of Moderate Buy. The company reported Q3 EPS of $0.35, missing the consensus estimate of $0.36.